Regarding "in situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992 to 1998)".
Calligaro
K D
KD
D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use*; D001011:Aorta / Q000601:surgery*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000379:methods*; D020099:Coated Materials, Biocompatible; D006801:Humans; D011474:Prosthesis Design; D016459:Prosthesis-Related Infections / Q000601:surgery*; D012086:Reoperation; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*
D000904:Antibiotics, Antitubercular; D020099:Coated Materials, Biocompatible; D012293:Rifampin